Celiac disease faces new therapeutic possibilities as companies target underlying inflammation

Celiac disease affects roughly one in every hundred people worldwide, imposing a daily burden that goes far beyond dietary restrictions.

Currently, patients have no approved medicines and must rely on a strict gluten‑free diet, which often fails to prevent accidental exposure and its symptoms.

The medical community is now viewing celiac as a distinct therapeutic area, recognizing a clear unmet need for treatments that address the disease’s underlying biology.

Companies such as First Tracks Biotherapeutics are exploring approaches that target inflammatory pathways, aiming to create the first disease‑modifying options for patients.